Skip to main content
iwCLL 2025 Main banner
Final Program


iwCLL X / Twitter

Poster

1515 - Re-Treatment with Venetoclax-Obinutuzumab after time-limited, MRD-guided Venetoclax-Obinutuzumab: final analysis of 7 patients with chronic lymphatic leukemia (CLL) treated in the CLL2-BAG trial of the GCLLSG.

    Primary Author / Presenter(s)

  • LM

    Léa Mazot

    Department I of Internal Medicine and Center of Integrated Oncology Cologne-Bonn, German CLL Study Group, University Hospital, Cologne, Germany
    Cologne, Nordrhein-Westfalen, Germany

    • Co-Author(s)

  • SR

    Sandra Robrecht

    Faculty of Medicine and University Hospital Cologne
    Department I of Internal Medicine and Center of Integrated Oncology Cologne-Bonn, German CLL Study Group, University Hospital
    Cologne, Nordrhein-Westfalen, Germany

  • AG

    Adam Giza, MSc

    ST
    Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne and Duesseldorf, German CLL Study Group, Faculty of Medicine and University Hospital Cologne, University of Cologne
    Cologne, Germany

  • AF

    Anna-Maria Fink

    Faculty of Medicine and University Hospital Cologne
    Department I of Internal Medicine and Center of Integrated Oncology Cologne-Bonn, German CLL Study Group, University Hospital
    Cologne, Nordrhein-Westfalen, Germany

  • Jv

    Julia v. Tresckow

    Department for Hematology, Oncology and Palliative Care, Catholic Clinic Bochum, Ruhr Univer-sity Bochum, Germany
    Bochum, Nordrhein-Westfalen, Germany

  • Petra Langerbeins, MD

    Faculty of Medicine and University Hospital Cologne
    Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf; German CLL Study Group, University of Cologne
    Cologne, Germany

  • Florian Simon

    Faculty of Medicine and University Hospital Cologne
    Department I of Internal Medicine and Center of Integrated Oncology Cologne-Bonn, German CLL Study Group, University Hospital
    Cologne, Nordrhein-Westfalen, Germany

  • MF

    Moritz Fürstenau, MD

    Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne and Duesseldorf, German CLL Study Group, Faculty of Medicine and University Hospital Cologne, University of Cologne
    Cologne, Germany

  • Othman Al-Sawaf, MD

    Faculty of Medicine
    Department I of Internal Medicine and Center of Integrated Oncology Cologne-Bonn, German CLL Study Group, University Hospital
    Cologne, Germany

  • Kirsten Fischer

    Faculty of Medicine and University Hospital Cologne
    Department I of Internal Medicine and Center of Integrated Oncology Cologne-Bonn, German CLL Study Group, University Hospital
    Department I of Internal Medicine, Center for Integrated Oncology Aachen-Bonn-Cologne-Duesseldorf, University Hospital Cologne and University of Cologne
    Cologne, Nordrhein-Westfalen, Germany

  • Eugen Tausch, MD

    Treating Physician and Research Fellow
    Division of CLL, Department of Internal Medicine III, University Hospital Ulm
    Ulm, Germany

  • LF

    Ludwig Fischer von Weikersthal

    Gesundheitszentrum St. Marien, Amberg, Germany
    Amberg, Bayern, Germany

  • CW

    Clemens-Martin Wendtner

    Department of Internal Medicine III, Ludwig-Maximilians University (LMU), Munich, Germany
    Munich, Bayern, Germany

  • KK

    Karl Kreuzer, MD

    Department I of Internal Medicine and Center of Integrated Oncology Cologne-Bonn, German CLL Study Group, University Hospital
    Cologne, Germany

  • SB

    Sebastian Böttcher, MD

    Clinic for Internal Medicine III (Hematology, Oncology, Palliative Care), Rostock University Medical School
    Rostock, Germany

  • MR

    Matthias Ritgen, MD

    University of Schleswig-Holstein, Campus Kiel
    Kiel, Schleswig-Holstein, Germany

  • Stephan Stilgenbauer, MD

    Professor of Medicine, Medical Director
    Division of CLL, Internal Medicine III, Ulm University
    Ulm, Baden-Wurttemberg, Germany

  • Barbara Eichhorst, MD

    Associate Professor, Consultant Hematologist
    Department I of Internal Medicine, University Hospital of Cologne
    Cologne, Germany

  • Michael Hallek, MD, PhD

    Principal Investigator, Director of Department I of Internal Medicine
    German CLL Study Group, University Hospital of Cologne
    Cologne, Germany

  • Paula Cramer, MD

    Faculty of Medicine and University Hospital Cologne
    Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf; German CLL Study Group, University of Cologne
    Cologne, Germany